{"id":"delstrigo","rwe":[],"tags":[],"safety":{"boxedWarnings":["WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B (HBV) have been reported in people with concomitant HIV-1 and HBV who have discontinued lamivudine or tenofovir disoproxil fumarate (TDF), which are components of DELSTRIGO. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue DELSTRIGO. If appropriate, initiation of ant"],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Neuropsychiatric adverse events","drugRate":"24%","severity":"mild to moderate","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Abnormal dreams","drugRate":"","severity":"common","organSystem":""},{"effect":"Sleep disorders and disturbances","drugRate":"","severity":"mild to moderate","organSystem":""},{"effect":"Depression","drugRate":"4%","severity":"mild to moderate","organSystem":""},{"effect":"Altered sensorium","drugRate":"","severity":"mild to moderate","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Suicide/self-injury","drugRate":"4%","severity":"serious"},{"effect":"Adverse events leading to discontinuation","drugRate":"3%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL2364608","moleculeType":"Small molecule","molecularWeight":"425.75"},"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$82.6907/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$30,182","description":"DELSTRIGO 100-300-300 MG TAB","retrievedDate":"2026-04-07"}],"offLabel":[],"timeline":[],"_dailymed":{"setId":"cd1e9f84-607a-46d3-b01e-2736018d67b6","title":"DELSTRIGO (DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [MERCK SHARP & DOHME LLC]"},"ecosystem":[],"mechanism":{},"_scrapedAt":"2026-03-28T00:32:10.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05630638","phase":"PHASE4","title":"Doravirine Dose Optimisation in Pregnancy","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-10-10","conditions":"HIV","enrollment":76},{"nctId":"NCT07357584","phase":"PHASE4","title":"Efficacy and Safety of Doravirine in the Rapid Initiation","status":"NOT_YET_RECRUITING","sponsor":"Fundación Huésped","startDate":"2026-07-13","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT06203132","phase":"PHASE3","title":"DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-01-27","conditions":"HIV-1-infection","enrollment":610},{"nctId":"NCT04233372","phase":"PHASE4","title":"Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2020-08-27","conditions":"Hiv","enrollment":399},{"nctId":"NCT06034938","phase":"PHASE2","title":"DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)","status":"RECRUITING","sponsor":"University Hospital, Caen","startDate":"2024-02-08","conditions":"Hiv","enrollment":32},{"nctId":"NCT04665375","phase":"PHASE4","title":"Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2021-04-26","conditions":"Hiv, Weight Gain","enrollment":4},{"nctId":"NCT05924438","phase":"PHASE3","title":"A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Professor Francois Venter","startDate":"2023-11-08","conditions":"HIV-1-infection","enrollment":600},{"nctId":"NCT04283656","phase":"PHASE1","title":"Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-01-04","conditions":"Transgender Health, Gender Dysphoria, Transgender Women","enrollment":8},{"nctId":"NCT05477407","phase":"NA","title":"Adipose Tissue After Switch to Doravirine","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2022-10-06","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT05289986","phase":"PHASE4","title":"The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients","status":"TERMINATED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2023-11-21","conditions":"Hiv","enrollment":18},{"nctId":"NCT02397096","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-06-09","conditions":"HIV-1 Infection","enrollment":673},{"nctId":"NCT05761509","phase":"","title":"\"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk\"","status":"COMPLETED","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2023-06-08","conditions":"HIV Infections","enrollment":226},{"nctId":"NCT04433780","phase":"PHASE3","title":"DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2021-01-04","conditions":"HIV-1-infection","enrollment":133},{"nctId":"NCT05457530","phase":"PHASE3","title":"Doravirine and Weight Gain in Antiretroviral Naive","status":"WITHDRAWN","sponsor":"Prism Health North Texas","startDate":"2022-08-01","conditions":"Body Weight Changes, Human Immunodeficiency Virus, ART","enrollment":""},{"nctId":"NCT04429152","phase":"PHASE3","title":"ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance","status":"UNKNOWN","sponsor":"Professor Francois Venter","startDate":"2021-02-09","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT02629822","phase":"PHASE2","title":"Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-14","conditions":"HIV-1 Infection","enrollment":10},{"nctId":"NCT04903847","phase":"PHASE4","title":"Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil","status":"UNKNOWN","sponsor":"Thomas Benfield","startDate":"2021-02-02","conditions":"Hiv, HIV Infections, HIV Lipodystrophy","enrollment":126}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20241107","type":"SUPPL","sponsor":"MSD MERCK CO","applicationNumber":"NDA210807"},{"date":"20180830","type":"ORIG","sponsor":"MSD MERCK CO","applicationNumber":"NDA210807"},{"date":"20191010","type":"SUPPL","sponsor":"MSD MERCK CO","applicationNumber":"NDA210807"},{"date":"20250612","type":"SUPPL","sponsor":"MSD MERCK CO","applicationNumber":"NDA210807"},{"date":"20220127","type":"SUPPL","sponsor":"MSD MERCK CO","applicationNumber":"NDA210807"},{"date":"20190919","type":"SUPPL","sponsor":"MSD MERCK CO","applicationNumber":"NDA210807"},{"date":"20251029","type":"SUPPL","sponsor":"MSD MERCK CO","applicationNumber":"NDA210807"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":8,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Delstrigo","genericName":"Delstrigo","companyName":"Hospital Clinic of Barcelona","companyId":"hospital-clinic-of-barcelona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}